YU47934B - Novi derivati ksantina sa antagonističnim dejstvom prema adenziju - Google Patents

Novi derivati ksantina sa antagonističnim dejstvom prema adenziju

Info

Publication number
YU47934B
YU47934B YU242389A YU242389A YU47934B YU 47934 B YU47934 B YU 47934B YU 242389 A YU242389 A YU 242389A YU 242389 A YU242389 A YU 242389A YU 47934 B YU47934 B YU 47934B
Authority
YU
Yugoslavia
Prior art keywords
substd
opt
alkyl
cycloalkyl
alkenyl
Prior art date
Application number
YU242389A
Other languages
English (en)
Other versions
YU242389A (en
Inventor
K.U. Muhl
H.K. Weber
G. Walther
W. Stransky
H. Ensinger
G. Schingnitz
J.F. Kuhn
E. Lehr
Original Assignee
Boehringer Ingelheim Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Kg. filed Critical Boehringer Ingelheim Kg.
Priority to SI8912423A priority Critical patent/SI8912423B/sl
Publication of YU242389A publication Critical patent/YU242389A/xx
Priority to HRP-2423/89A priority patent/HRP940724A2/hr
Publication of YU47934B publication Critical patent/YU47934B/sh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

NOVI DERIVATI KSANTINA SA ANTAGONISTIČNIM DEJSTVOM PREMA ADENZIJU, novi ksantini opšte formule I u kojoj R1 označava alkil-grupu, sa 1 do 4, atoma ugljenika; R2 označava alkil-grupu, sa 1 do 4, atoma ugljenika; R3 označava furan, supstituisan sa CONR5R6; R3 označava tetrahidropiran-4-il ili ditiolan; R3 označava C5-cikloalkanon ili C5-cikloalkanol; R3 označava C5-cikloalkan, koji je supstituisan sa C1 do C6, prvenstveno C1 do C4-alkil, =CH2, OR4, OR7, -CH2-OH, -OCONH-fenil ili =N-NH-fenil-grupom, pri čemu fenil-ostatak može da bude supstituisan, ili sa ostatkom =CAH, pri čemu A može da predstavlja COOR4; ili cikloalkan, supstituisan metil-grupom, a kao drugi supstituent sadrži hidroksil-grupu u geminalnom položaju u odnosu na prvi supstituent; R3 označava ostatak formule R4 označava vodonik, alkil-grupu sa 1 do 6 atoma ugljenika; R5 označava vodonik, alkil-grupu sa 1 do 4 atoma ugljenika; R6 označava vodonik, alkil-grupu sa 1 do 6 atoma ugljenika, eventualno supstituisanu benzil-grupu, ostatak opšte formule -(CH2)n-NR5R5 (R5 isti ili različiti), sa n=2, piperidinil-ostatak vezan preko ugljenika, koji je eventualno supstituisan sa C1 do C4-alikl-grupom ili sa benzil-ostatkom vezanim preko azota; R7 označava CO-C1-C13-alkil, prvenstveno CO-C2-C4-alkil, eventual-no supstituisan benzoil-ostatak, prevenstveno trimetoksibenzoil, os-tatak opšte formule CO-piridinil, eventualno kao i njihove racemate, njihova optički aktivna jedinjenja kao i njihove adicione soli sa kiselinama. Prijava sadrži još 4 nezavis-na i 1 zavisan zahtev.
YU242389A 1988-12-22 1989-12-20 Novi derivati ksantina sa antagonističnim dejstvom prema adenziju YU47934B (sh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI8912423A SI8912423B (sl) 1988-12-22 1989-12-20 Novi derivati ksantina z antagonističnim učinkom proti adenozinu
HRP-2423/89A HRP940724A2 (en) 1988-12-22 1994-10-21 Novel xantin derivatives having an adenosin-antagonistic activity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3843117A DE3843117A1 (de) 1988-12-22 1988-12-22 Neue xanthinderivate mit adenosin-antagonistischer wirkung

Publications (2)

Publication Number Publication Date
YU242389A YU242389A (en) 1991-10-31
YU47934B true YU47934B (sh) 1996-05-20

Family

ID=6369764

Family Applications (1)

Application Number Title Priority Date Filing Date
YU242389A YU47934B (sh) 1988-12-22 1989-12-20 Novi derivati ksantina sa antagonističnim dejstvom prema adenziju

Country Status (32)

Country Link
US (4) US5175291A (sh)
EP (1) EP0374808B1 (sh)
JP (1) JP2565576B2 (sh)
KR (1) KR0165666B1 (sh)
AT (1) ATE136897T1 (sh)
BG (1) BG61669B2 (sh)
BR (1) BR1100527A (sh)
CA (1) CA2006387C (sh)
CZ (1) CZ286230B6 (sh)
DD (1) DD290421A5 (sh)
DE (3) DE3843117A1 (sh)
DK (1) DK652689A (sh)
ES (1) ES2086313T3 (sh)
FI (1) FI96513C (sh)
GR (1) GR3019733T3 (sh)
HR (1) HRP940724A2 (sh)
HU (1) HU218674B (sh)
IE (1) IE74205B1 (sh)
IL (1) IL92829A (sh)
MX (1) MX9203618A (sh)
NO (1) NO173502C (sh)
NZ (1) NZ231901A (sh)
PH (2) PH31107A (sh)
PL (1) PL162877B1 (sh)
PT (1) PT92658B (sh)
RU (1) RU2057752C1 (sh)
SG (1) SG46380A1 (sh)
SI (1) SI8912423B (sh)
SK (1) SK719789A3 (sh)
UA (1) UA26427A (sh)
YU (1) YU47934B (sh)
ZA (1) ZA899881B (sh)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) * 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
GB9111131D0 (en) * 1991-05-23 1991-07-17 Ici Plc Heterocyclic compounds
GB9111130D0 (en) * 1991-05-23 1991-07-17 Ici Plc Azole derivatives
CA2082325A1 (en) * 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives
IT1260444B (it) * 1992-01-24 1996-04-09 Mario Brufani Derivati della 8-(1-amminocicloalchil)1,3-dialchilxantina, procedimenbto di preparazione e loro composizioni farmaceutiche antidepressive, nootropiche e psicostimolanti
EP0556778A3 (en) * 1992-02-17 1993-11-24 Kyowa Hakko Kogyo Kk Xanthine derivatives
US5484920A (en) * 1992-04-08 1996-01-16 Kyowa Hakko Kogyo Co., Ltd. Therapeutic agent for Parkinson's disease
CA2093403C (en) * 1992-04-08 1999-08-10 Fumio Suzuki Therapeutic agent for parkinson's disease
WO1994003173A1 (de) * 1992-08-01 1994-02-17 Boehringer Ingelheim Kg Verwendung von 8-(3-oxocyclopentyl)-1,3-dipropyl-7h-purin-2,6-dion zur symptomatischen behandlung der zystischen fibrose
TW252044B (sh) * 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
US5288721A (en) * 1992-09-22 1994-02-22 Cell Therapeutics, Inc. Substituted epoxyalkyl xanthines
JP2613355B2 (ja) * 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
US5877179A (en) * 1992-09-29 1999-03-02 The United States Of America As Represented By The Department Of Health And Human Services Xanthines for identifying CFTR--binding compounds useful for activating chloride conductance in animal cells
DE4236331A1 (de) * 1992-10-28 1994-05-05 Boehringer Ingelheim Kg Synergistische Kombination
AU6087894A (en) * 1993-01-14 1994-08-15 Cell Therapeutics, Inc. Acetal or ketal substituted therapeutic compounds
WO1994019349A1 (en) * 1993-02-26 1994-09-01 Merrell Dow Pharmaceuticals Inc. Xanthine derivatives as adenosine a1 receptor antagonists
WO1994025462A1 (en) * 1993-05-03 1994-11-10 The United States Of America, Represented By The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
US5736528A (en) * 1993-10-28 1998-04-07 University Of Florida Research Foundation, Inc. N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists
JP3769737B2 (ja) * 1994-03-30 2006-04-26 味の素株式会社 シクロプロパン誘導体及びその製造法
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
ATE247655T1 (de) * 1994-12-13 2003-09-15 Euro Celtique Sa Dreifachsubstituierte thioxanthine
DE69531506T2 (de) * 1994-12-13 2004-06-24 Euroceltique S.A. Arylthioxanthine
US5864037A (en) * 1996-06-06 1999-01-26 Euro-Celtique, S.A. Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
ATE325610T1 (de) * 1997-09-05 2006-06-15 Kyowa Hakko Kogyo Kk Xanthinderivative zur behandlung von hirnischämie
US6248746B1 (en) 1998-01-07 2001-06-19 Euro-Celtique S.A. 3-(arylalkyl) xanthines
DE19816857A1 (de) * 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO1999062553A1 (fr) * 1998-06-01 1999-12-09 Fujisawa Pharmaceutical Co., Ltd. Medicaments contre la sterilite masculine
AU4980999A (en) 1998-07-10 2000-02-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The A3 adenosine receptor antagonists
US6025362A (en) * 1998-08-31 2000-02-15 Fukunaga; Atsuo F. Uses of xanthine compounds
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
BR0015540A (pt) * 1999-11-12 2002-07-23 Biogen Inc Antagonistas do receptor de adenosina e métodos de preparação e uso dos mesmos
SI1230243T1 (sl) * 1999-11-12 2009-08-31 Biogen Idec Inc Policikloalkilpurini kot antagonisti adenozinskega receptorja
WO2001051490A1 (en) 2000-01-14 2001-07-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Methanocarba cycloalkyl nucleoside analogues
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US6977300B2 (en) * 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20080318983A1 (en) * 2001-11-09 2008-12-25 Rao Kalla A2b adenosine receptor antagonists
US7125993B2 (en) * 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
CN100467469C (zh) * 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
AU2003261206A1 (en) * 2002-07-19 2004-02-09 Aryx Therapeutics Xanthine derivatives having adenosine a1-receptor antagonist properties
EP1601649A4 (en) * 2003-02-19 2009-03-04 Endacea Inc A1-adenosine receptor antagonistic
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
US20060293312A1 (en) * 2003-04-25 2006-12-28 Howard Dittrich Method of improved diuresis in individuals with impaired renal function
RU2367442C2 (ru) * 2003-04-25 2009-09-20 Новокардия, Инк. Способ нормализации мочеиспускания при нарушении функции почек
DK1622908T3 (da) * 2003-05-06 2008-11-17 Cv Therapeutics Inc Xanthin-derivater som A2B adenosin-receptor-antagonister
CA2528385C (en) * 2003-06-06 2011-03-15 Endacea, Inc. A1 adenosine receptor antogonists
EP1636230A4 (en) * 2003-06-09 2010-06-16 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
TW200507882A (en) * 2003-07-17 2005-03-01 Kyowa Hakko Kogyo Kk Solid formulations
US6847249B1 (en) * 2003-10-09 2005-01-25 Analog Devices, Inc. Highest available voltage selector circuit
JP2007532671A (ja) * 2004-04-16 2007-11-15 ノヴァカーディア，インク． アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法
SI1789053T1 (sl) * 2004-09-01 2012-09-28 Gilead Sciences Inc Postopek celjenja rane z uporabo antagonistov A2B adenozinskih receptorjev
JP2009540003A (ja) * 2006-06-16 2009-11-19 ノヴァカーディア，インク． Ａａ１ｒａの低頻度投与を含む腎機能の長期間にわたる改善
US8193200B2 (en) 2007-01-04 2012-06-05 University Of Virginia Patent Foundation Antagonists of A2B adenosine receptors for treatment of inflammatory bowel disease
WO2008121882A1 (en) * 2007-03-29 2008-10-09 Novacardia, Inc. Improved methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
CN102015712A (zh) * 2008-03-26 2011-04-13 阿德维纳斯治疗私人有限公司 作为腺苷受体拮抗剂的杂环化合物
US8129862B2 (en) * 2009-10-23 2012-03-06 Analog Devices, Inc. Scalable highest available voltage selector circuit
JP5843778B2 (ja) * 2009-11-09 2016-01-13 アドヴィナス・セラピューティックス・リミテッド 置換縮合ピリミジン化合物、その調製およびその使用
WO2011068978A1 (en) 2009-12-02 2011-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives and dendrimer conjugates thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1201997A (en) * 1967-08-04 1970-08-12 Yissum Res Dev Co New substituted purines and purine derivatives
US3624215A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-anxiety agents
US3624216A (en) * 1970-06-25 1971-11-30 Abbott Lab 8-substituted theophyllines as anti-inflammatory agents
DE3028273A1 (de) * 1980-07-25 1982-02-25 Fa. Dr. Willmar Schwabe, 7500 Karlsruhe Durch purinbasen substituierte 1.4;3.6-dianhydro-hexit-nitrate
ES8401072A1 (es) * 1982-11-23 1983-12-16 Faes Procedimiento de preparacion de un nuevo espirodecano.
US4593095A (en) * 1983-02-18 1986-06-03 The Johns Hopkins University Xanthine derivatives
US4548939A (en) * 1984-10-01 1985-10-22 Janssen Pharmaceutica N. V. 1H-Indol-3-yl containing 1,3-dimethyl-1H-purine-2,6-diones
US4755517A (en) * 1986-07-31 1988-07-05 Warner-Lambert Company Derivatives of xanthine, pharmaceutical compositions and methods of use therefor
US5175290A (en) * 1988-09-16 1992-12-29 Marion Merrell Dow Inc. 8-(oxo-substituted cycloalkyl)xanthines
DE3843117A1 (de) * 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) * 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
US4957921A (en) * 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
CA2082325A1 (en) * 1991-11-08 1993-05-09 Fumio Suzuki Xanthine derivatives

Also Published As

Publication number Publication date
IE894147L (en) 1990-06-22
BG61669B2 (bg) 1998-02-27
CZ286230B6 (cs) 2000-02-16
DK652689D0 (da) 1989-12-21
EP0374808B1 (de) 1996-04-17
UA26427A (uk) 1999-08-30
IE74205B1 (en) 1997-07-16
PH31111A (en) 1998-02-23
RU2057752C1 (ru) 1996-04-10
NO895168D0 (no) 1989-12-21
FI896117A0 (fi) 1989-12-20
ATE136897T1 (de) 1996-05-15
SG46380A1 (en) 1998-02-20
NO895168L (no) 1990-06-25
EP0374808A3 (de) 1991-05-15
HRP940724A2 (en) 1997-06-30
DE3843117A1 (de) 1990-06-28
DE8817122U1 (sh) 1993-02-04
PL282878A1 (en) 1992-03-09
HU896736D0 (en) 1990-02-28
PT92658A (pt) 1990-06-29
DK652689A (da) 1990-06-23
SI8912423A (sl) 1998-04-30
NO173502B (no) 1993-09-13
JPH02247180A (ja) 1990-10-02
MX9203618A (es) 1992-09-01
SK279525B6 (sk) 1998-12-02
IL92829A0 (en) 1990-09-17
US5175291A (en) 1992-12-29
US5696124A (en) 1997-12-09
SK719789A3 (en) 1998-12-02
PT92658B (pt) 1995-09-12
CZ719789A3 (cs) 1999-10-13
EP0374808A2 (de) 1990-06-27
NO173502C (no) 1993-12-22
PL162877B1 (pl) 1994-01-31
US5688802A (en) 1997-11-18
US5532368A (en) 1996-07-02
BR1100527A (pt) 2000-08-01
DE58909657D1 (de) 1996-05-23
NZ231901A (en) 1993-12-23
YU242389A (en) 1991-10-31
FI96513C (fi) 1996-07-10
CA2006387A1 (en) 1990-06-22
AU4707289A (en) 1990-06-28
ZA899881B (en) 1991-08-28
JP2565576B2 (ja) 1996-12-18
GR3019733T3 (en) 1996-07-31
HUT52503A (en) 1990-07-28
KR0165666B1 (ko) 1999-01-15
ES2086313T3 (es) 1996-07-01
DD290421A5 (de) 1991-05-29
FI96513B (fi) 1996-03-29
CA2006387C (en) 2000-02-08
IL92829A (en) 1995-12-31
SI8912423B (sl) 1998-12-31
PH31107A (en) 1998-02-23
AU637990B2 (en) 1993-06-17
KR900009646A (ko) 1990-07-05
HU218674B (hu) 2000-10-28

Similar Documents

Publication Publication Date Title
YU47934B (sh) Novi derivati ksantina sa antagonističnim dejstvom prema adenziju
DK148279C (da) Analogifremgangsmaade til fremstilling af 9-substituerede guaninderivater eller fysiologisk acceptable salte eller optiske isomerer deraf
ES2090507T3 (es) Procedimiento para la preparacion de simvastatina.
DK653088D0 (da) Anti-inflammatoriske derivater af di-tert-butylphenolforbindelser og farmaceutisk middel omfattende samme
KR850003533A (ko) 1,3-디옥산 유도체의 제조방법
FR2671349B1 (fr) Nouveaux derives de 1,4-dihydropyridine, leur procede de preparation et composition therapeutique les contenant.
KR860002508A (ko) 푸로(3,2-c)피리딘 유도체, 그의 제법 및 그를 포함하는 의약 조성물
ES2128332T3 (es) Metodo para la produccion de la 2-amino-6-halogenopurina y sintesis de un intermediario.
US4086247A (en) 3-(1'-Hydroxy-2'-hydroxyethyl)-4,6-dihydroxyhexanoic acid 4γ lactone derivatives
Troyansky et al. Remote asymmetric induction in free radical cycloaddition leading to trans-cyclohexano-fused 12-membered crown thioethers
KR830007592A (ko) 약리활성체 4-[2-히드록시-4-(치환)페닐]나프탈렌-2(1h)-온 및 2-올, 이들 유도체 및 이들 중간체의 제조방법
ATE110079T1 (de) Triazolo(1,5-c>pyrimido(1,4>azine als bronchodilatatoren.
GB1494758A (en) Prostaglandin intermediates
FR2579813B1 (fr) Procede de synthese sonore par composition d'interceptions de rayons lumineux